. 2021 Nov 1;13(21):5500. doi: 10.3390/cancers13215500

Table 3.

Characteristics of the molecular subtypes using NanoStringnCounter analysis in the current study of 91 urothelial carcinoma (UC) samples.

Molecular Subtypes (n, %)	Histological Subtypes (n; %)	T Stage Category (n)	High PD-L1 Expression (%)	Survival Status, Median ±SD (Range), in Months
LUMINAL (65; 71%) GATA3⁺ and/or KRT20⁺	Conventional UC (55; 84.6%)	Ta (31); T1 (21); T2–T4 (3)	15 (27.3%)	49 ± 35.70 (12–125)
LUMINAL (65; 71%) GATA3⁺ and/or KRT20⁺	Variant histology UC (10; 15.4%) (Micropapillary (4); Nested (1); Plasmacytoid (1); Other Variants (4))	Ta (0); T1 (6); T2–T4 (4)	4 (40%)	45 ± 55.36 (4–119)
BASAL (19; 21%) KRT5⁺ and/or KRT14⁺; GATA3⁻; KRT20⁻	Conventional UC (8; 42.1%)	Ta (3); T1 (3); T2–T4 (2)	4 (50%)	21 ± 7.34 (12–60)
BASAL (19; 21%) KRT5⁺ and/or KRT14⁺; GATA3⁻; KRT20⁻	Variant histology UC (11; 57.9%) (Micropapillary (2); Nested (4); Plasmacytoid (2); Other Variants (3))	Ta (0), T1 (0); T2–T4 (11)	8 (72.7%)	9.5 ± 21.42 (2–21)
NULL/DOUBLE NEGATIVE (7; 8%) GATA3⁻; KRT20⁻; KRT5⁻; KRT14⁻	Conventional UC (4; 57.1%)	Ta (2); T1 (0); T2–T4 (2)	2 (66.7%)	32 ± 36.77 (6–58)
NULL/DOUBLE NEGATIVE (7; 8%) GATA3⁻; KRT20⁻; KRT5⁻; KRT14⁻	Variant histology UC (3; 42.9%) (Nested (1); Plasmacytoid (2))	Ta (0); T1 (0); T2–T4 (3)	3 (100%)	4 ± 1.15 (2–4)